Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ESLA NASDAQ:GRML NASDAQ:LIAN NASDAQ:LITS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeESLAEstrella Immunopharma$0.78+2.0%$1.00$0.73▼$3.15$32.90M0.8547,738 shs78,743 shsGRMLGreenland Mines Ltd. Common Stock$0.19-3.9%$0.28$0.16▼$1.28$26.60M7.058.96 million shs6.25 million shsLIANLianBio$0.05-7.1%$0.12$0.27▼$4.99$5.62M0.231.04 million shs35,200 shsLITSLite Strategy$0.99-0.3%$0.94$0.69▼$6.88$33.75M0.21178,146 shs161,969 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceESLAEstrella Immunopharma+2.04%-7.14%-20.41%-50.63%-13.33%GRMLGreenland Mines Ltd. Common Stock-3.94%-7.89%-15.60%-60.26%-84.83%LIANLianBio-20.00%-49.37%-49.46%-54.10%+3.70%LITSLite Strategy-0.34%+0.18%+13.22%-16.24%+98,839,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeESLAEstrella Immunopharma$0.78+2.0%$1.00$0.73▼$3.15$32.90M0.8547,738 shs78,743 shsGRMLGreenland Mines Ltd. Common Stock$0.19-3.9%$0.28$0.16▼$1.28$26.60M7.058.96 million shs6.25 million shsLIANLianBio$0.05-7.1%$0.12$0.27▼$4.99$5.62M0.231.04 million shs35,200 shsLITSLite Strategy$0.99-0.3%$0.94$0.69▼$6.88$33.75M0.21178,146 shs161,969 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceESLAEstrella Immunopharma+2.04%-7.14%-20.41%-50.63%-13.33%GRMLGreenland Mines Ltd. Common Stock-3.94%-7.89%-15.60%-60.26%-84.83%LIANLianBio-20.00%-49.37%-49.46%-54.10%+3.70%LITSLite Strategy-0.34%+0.18%+13.22%-16.24%+98,839,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceESLAEstrella Immunopharma 2.00Hold$8.00925.64% UpsideGRMLGreenland Mines Ltd. Common Stock 1.00SellN/AN/ALIANLianBio 0.00N/AN/AN/ALITSLite Strategy 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest LIAN, ESLA, LITS, and GRML Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/21/2026ESLAEstrella Immunopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)7/17/2026LITSLite Strategy Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)7/15/2026GRMLGreenland Mines Ltd. Common Stock Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/29/2026GRMLGreenland Mines Ltd. Common Stock Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/12/2026ESLAEstrella Immunopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/9/2026GRMLGreenland Mines Ltd. Common Stock Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/1/2026LITSLite Strategy Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)5/28/2026ESLAEstrella Immunopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/14/2026ESLAEstrella Immunopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/29/2026ESLAEstrella Immunopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)(Data available from 7/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookESLAEstrella ImmunopharmaN/AN/AN/AN/A($0.27) per shareN/AGRMLGreenland Mines Ltd. Common StockN/AN/AN/AN/A$0.13 per shareN/ALIANLianBioN/AN/AN/AN/A$2.71 per shareN/ALITSLite Strategy$65.30M0.52$5.81 per share0.17N/A∞Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateESLAEstrella Immunopharma-$13.06M-$0.34N/AN/AN/AN/AN/A-397.36%9/2/2026 (Estimated)GRMLGreenland Mines Ltd. Common Stock-$10.55M-$0.32N/AN/AN/AN/A-109.40%-98.80%N/ALIANLianBio-$110.29M-$0.81N/AN/AN/AN/A-33.17%-30.19%N/ALITSLite Strategy-$15.94M-$1.60N/AN/AN/AN/A-90.81%-89.33%N/ALatest LIAN, ESLA, LITS, and GRML EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/20/2026Q1 2026GRMLGreenland Mines Ltd. Common StockN/A-$0.15N/A-$0.15N/AN/A5/16/2026Q1 2026ESLAEstrella Immunopharma-$0.0840-$0.05+$0.0340-$0.05N/AN/A5/13/2026Q3 2026LITSLite StrategyN/A-$0.66N/A-$0.66N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthESLAEstrella ImmunopharmaN/AN/AN/AN/AN/AGRMLGreenland Mines Ltd. Common StockN/AN/AN/AN/AN/ALIANLianBioN/AN/AN/AN/AN/ALITSLite StrategyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioESLAEstrella ImmunopharmaN/A0.240.24GRMLGreenland Mines Ltd. Common StockN/A19.7319.73LIANLianBioN/A10.0610.06LITSLite StrategyN/A11.5311.53Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipESLAEstrella Immunopharma0.35%GRMLGreenland Mines Ltd. Common Stock20.07%LIANLianBio74.85%LITSLite Strategy52.38%Insider OwnershipCompanyInsider OwnershipESLAEstrella Immunopharma5.80%GRMLGreenland Mines Ltd. Common Stock11.30%LIANLianBio7.59%LITSLite Strategy1.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableESLAEstrella ImmunopharmaN/A43.03 million40.54 millionNot OptionableGRMLGreenland Mines Ltd. Common Stock5138.13 million122.52 millionN/ALIANLianBio110108.06 million99.86 millionNot OptionableLITSLite Strategy10034.03 million33.48 millionN/ALIAN, ESLA, LITS, and GRML HeadlinesRecent News About These CompaniesLite Strategy (NASDAQ:LITS) Director Acquires 25,000 Shares of StockJune 26, 2026 | insidertrades.comCan LitVM Bring Smart Contracts to Litecoin Without Changing Its Identity?June 23, 2026 | finance.yahoo.comLite Strategy, Inc. to Join Litecoin Foundation Summit Panel on Litecoin’s Institutional OpportunityJune 19, 2026 | quiverquant.comQLite Strategy to Attend Panel at Litecoin Foundation Summit in AmsterdamJune 19, 2026 | globenewswire.comExclusive: Lite Strategy leads $1m investment in Litecoin Layer 2 platform LitVMJune 19, 2026 | finance.yahoo.comLite Strategy Leads Strategic Investment in LitVMJune 18, 2026 | markets.businessinsider.comLite Strategy, Inc. Common Stock (LITS) SEC FilingsMay 20, 2026 | nasdaq.comLite Strategy Reports Fiscal 2026 Third Quarter ResultsMay 13, 2026 | globenewswire.comIs Lite Strategy (NASDAQ:LITS) In A Good Position To Invest In Growth?April 25, 2026 | finance.yahoo.comLite Strategy Inc.April 18, 2026 | barrons.comLite Strategy IncApril 8, 2026 | cnn.comLite Strategy, Inc. Common Stock (LITS) Institutional HoldingsApril 6, 2026 | nasdaq.comLite Strategy Inc LITSMarch 26, 2026 | morningstar.comMLite Strategy, Inc. Reports Second Quarter Fiscal 2026 Financial Results and Launches Active Treasury Management InitiativesFebruary 17, 2026 | quiverquant.comQLite Strategy Reports Fiscal 2026 Second Quarter ResultsFebruary 17, 2026 | globenewswire.comLiTHOS Announces Board and Management ChangeJanuary 14, 2026 | newsfilecorp.comNJames Flynn Acquires 70,000 Shares of Lite Strategy (NASDAQ:LITS) StockDecember 23, 2025 | insidertrades.comFive Days, Zero Inflows: Litecoin ETF Struggles to Break $7.44 MillionNovember 25, 2025 | finance.yahoo.comLite Strategy names acting CEO Justin File to role on a permanent basisNovember 20, 2025 | msn.comLite Strategy Reports First Quarter Fiscal Year 2026 Results, Highlights Successful Launch of $100 Million Litecoin Treasury Strategy and Movement Into Active Capital Market ...November 18, 2025 | dailyhodl.comDNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesPushing the Edge: Super Micro Computer Reboots the AI LandscapeBy Jeffrey Neal Johnson | July 11, 2026Tesla Stock Surges 15% as FSD Update Backs Its Autonomy ThesisBy Sam Quirke | July 2, 2026Ouster Is Breaking Out as a Physical AI Leader: Here's What's Driving the MoveBy Ryan Hasson | July 1, 2026Microsoft Bets on In-House AI to Cut OpenAI and Anthropic CostsBy Chris Markoch | July 12, 2026Best Buy’s Turnaround Is Gaining Traction, But Wall Street Still Needs ProofBy Peter Frank | June 30, 2026LIAN, ESLA, LITS, and GRML Company DescriptionsEstrella Immunopharma NASDAQ:ESLA$0.78 +0.02 (+2.04%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$0.79 +0.01 (+1.28%) As of 07/24/2026 05:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.Greenland Mines Ltd. Common Stock NASDAQ:GRML$0.19 -0.01 (-3.94%) As of 07/24/2026 04:00 PM EasternGreenland Mines Ltd develops essential medicines for the treatment of chronic diseases - cancer, cardiovascular, and neurodegenerative disorders. The Company operates as a single reporting segment focused on developing essential medicines for these chronic diseases. The Company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and proprietary patented technologies involving melanocortin receptor-binding molecules and a gene therapy platform that introduces a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases.LianBio NASDAQ:LIAN$0.05 0.00 (-7.14%) As of 07/24/2026LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor and NX-13 for ulcerative colitis and Crohn's disease; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus. It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03 for the treatment of Demodex blepharitis; and Nanobiotix S.A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.Lite Strategy NASDAQ:LITS$0.99 0.00 (-0.34%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$0.98 -0.01 (-0.75%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex that is in Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer; and Pracinostat, an oral available histone deacetylase inhibitor, which is in Phase II clinical trial to treat patients with myelodysplastic syndrome. MEI Pharma, Inc. has a license, development, and commercialization agreement with Kyowa Kirin Company; a clinical collaboration with BeiGene, Ltd.; a license, development, manufacturing, and commercialization agreement with Helsinn Healthcare SA; and a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/20- 07/24 Telecom Earnings Reveal a Sector That Finally Looks Healthier AMD and Cerbras Create A New Blueprint For Hardware Intel Earnings Reveal Whether the Chip Selloff Created a Buy CrowdStrike’s Cerebras Deal Puts Its AI Security Strategy to the Test Defense Earnings Show Readiness Now and Modernization Ahead Freeport McMoRan Post-Earnings: Why Good Enough May Finally Be Good Enough Tesla Just Delivered Record Sales—So Why Did the Stock Sell Off? Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
